Skip to content
Clinical Trials – home
Not recruiting

Relative Bioavailability of AGMB-129 Tablet vs ORG-129 Capsule and Food Effect in Healthy Participants for Fibrostenotic Crohn’s Disease

InvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves a condition called Fibrostenotic Crohn’s disease, a form of Crohn’s disease where scar tissue causes narrowing of the intestine. The medication being examined is a new oral formulation named AGMB-129, which is taken as a tablet and is compared with an existing oral product called ORG-129, supplied as a capsule. Both contain the same active ingredient but are presented in different dosage forms.

The main purpose is to determine how much of the drug reaches the bloodstream (known as bioavailability) when given as a tablet compared with the capsule, and to see whether eating food changes this amount. Participants will receive a single dose of each form in separate study periods, with a short break between doses, and some doses will be taken after a meal while others will be taken on an empty stomach. Blood samples will be collected to measure the drug and its breakdown products, which is part of the pharmacokinetic assessment.

Throughout the study, participants will be monitored for any side effects, with regular checks of vital signs, basic laboratory tests, and a physical examination to ensure safety. Any unwanted symptoms or health changes will be recorded and evaluated by the study team.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Consent and Baseline Assessments

    You provide written consent to participate in the study and confirm that you meet the eligibility criteria.

    Baseline evaluations are performed, including medical history, physical examination, vital signs, and laboratory tests to ensure you are healthy enough for the trial.

  2. Step 2

    First Dosing Period

    You receive a single oral dose of 200 mg of either the AGMB-129 tablet or the ORG-129 capsule, according to the random assignment.

    The dose is taken with water under either fasted or fed conditions, as specified for this period.

    After dosing, you remain in the clinic for several hours while blood samples are collected at predetermined times to measure drug levels.

    Your vital signs are checked regularly, and you are observed for any side effects.

  3. Step 3

    Washout Period

    A washout interval is observed to allow the study drug to clear from your body before the next dosing period.

    No study medication is taken during this time, and you continue normal activities while avoiding any prohibited medications.

  4. Step 4

    Second Dosing Period

    You receive a single oral dose of the alternative formulation: if you received the AGMB-129 tablet in the first period, you now take the ORG-129 capsule, and vice versa.

    The dose remains 200 mg and is taken with water under the opposite feeding condition (fed if the first dose was fasted, or fasted if the first dose was fed).

    Post‑dose monitoring is repeated, including blood sampling, vital‑sign checks, and observation for side effects.

  5. Step 5

    Second Washout Period

    A second washout interval is observed before the final dosing period, ensuring the previous dose is fully eliminated.

  6. Step 6

    Third Dosing Period

    You receive a single oral dose of 200 mg of the formulation assigned for the third period, which may repeat one of the earlier conditions to complete the cross‑over design.

    The same procedures for dosing, monitoring, and safety observation are followed as in the earlier periods.

  7. Step 7

    Final Assessments and Study Completion

    After the last monitoring session, final laboratory tests, vital‑sign measurements, and a physical examination are performed.

    All study data are reviewed, and you are informed that your participation in the trial is complete.

Who can join the trial?

11 criteria

  • Informed Consent Form signed voluntarily before any study procedures, showing you understand the study and agree to take part.
  • Willing to follow the lifestyle rules that are described in the study plan.
  • Be a man or woman who is between 18 and 55 years old (including the ages 18 and 55) on the day you sign the consent form.
  • Weigh at least 50 kg (110 lb) if you are male or at least 45 kg (99 lb) if you are female, and have a body mass index (BMI) between 19 and 30 kg/m² at the screening visit.
  • If you are male, you must either have had a vasectomy (a surgical procedure that stops sperm from being released) or agree to not donate sperm and to either stay abstinent from heterosexual intercourse (no vaginal sex) or use a male condom every time you have sex with a woman who could become pregnant, from screening until at least 4 weeks after the last dose.
  • If you are female, you must not be pregnant or breastfeeding and you must either be unable to become pregnant, or if you can become pregnant you must use a highly effective birth‑control method (less than 1 % chance of failure per year) or stay abstinent from heterosexual intercourse, and you must not donate eggs, from screening until at least 4 weeks after the last dose.
  • Female participants must have a negative, highly sensitive blood test for β‑hCG (a hormone that shows pregnancy) at screening and a negative urine pregnancy test the day before the first dose.
  • Be in good overall health based on your medical history, a physical exam, vital signs (like blood pressure and heart rate), and a 12‑lead ECG (a test that records the heart’s electrical activity), as judged by the study doctor.
  • Blood tests for liver health – specifically total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) – must be no more than 1.5 times the normal upper limit, and other lab results must be within normal ranges or considered not clinically important by the doctor.
  • Negative urine test for selected drugs of abuse (such as amphetamines, barbiturates, benzodiazepines, THC, cocaine, opiates, etc.) and a negative breath test for alcohol at screening and the day before the first dose.
  • Negative COVID‑19 PCR test (a test that looks for the virus’s genetic material) and no symptoms of COVID‑19 on the day before the first dose, if required by the study site.

Who cannot join the trial?

20 criteria

  • Known hypersensitivity (allergy) to any ingredient in AGMB-129, or a past serious allergic reaction to these ingredients.
  • Use of any medication that can cause major organ damage (known organ toxicity) within the 3 months before the first dose.
  • Use of any medicine, supplement, vitamin, or herbal product in the last 14 days (or for a period equal to five times the drug’s half‑life, whichever is longer), except for occasional paracetamol (no more than 2 g per day and 10 g in two weeks), ibuprofen taken during the study, hormonal birth control for women who could become pregnant, or hormone replacement therapy for post‑menopausal women.
  • Having received, or planning to receive, a live vaccine (a vaccine that contains a weakened form of the germ) within 4 weeks before the first dose. Emergency‑use vaccines such as COVID‑19 vaccines are allowed.
  • Being enrolled in another drug or drug/device study within 30 days (or five drug half‑lives, whichever is longer) or in a biologic (a medicine made from living cells) research study within 3 months (or five biologic half‑lives, whichever is longer) before the first dose.
  • Active drug abuse or alcohol abuse (drinking more than 14 units of alcohol per week) within the past 2 years.
  • Current smoking or use of e‑cigarettes, nicotine, or any nicotine‑containing products within the past 6 months.
  • Regular consumption of large amounts of caffeine‑containing foods or drinks (more than 6 cups of coffee, tea, cocoa, cola, or energy drinks per day).
  • Being the investigator, a member of the study staff, or a close relative of anyone directly involved in conducting the study.
  • Any health condition or situation at screening that the investigator believes could put your safety at risk, make it unlikely you could finish the study, or prevent you from following study procedures.
  • Having poor vein access that would limit the ability to take blood samples.
  • Testing positive for hepatitis B surface antigen or hepatitis C antibodies, or having a history of hepatitis (except hepatitis A that was fully resolved at least 3 months ago).
  • Lactose intolerance (difficulty digesting the sugar found in milk).
  • Having a current or past condition that weakens the immune system, including a positive test for HIV‑1 or HIV‑2 antibodies.
  • Current or past vasculitis (inflammation of blood vessels), heart valve disease, or large‑vessel problems such as an aneurysm (a balloon‑like bulge) or dissection (a tear in the vessel wall).
  • Any illness that the investigator considers medically important that occurred within the past 3 months.
  • Having gastrointestinal, liver, kidney (estimated glomerular filtration rate ≤ 80 mL/min/1.73 m²), or other disorders that could affect how the drug is absorbed, distributed, metabolized, or removed from the body.
  • History of cancer within the last 5 years, except for fully treated non‑metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • Clinically significant abnormalities on a 12‑lead ECG (heart rhythm test), such as a prolonged QT interval (> 450 ms). A first‑degree atrioventricular block is not considered significant.
  • Significant blood loss (including donating more than 450 mL of blood) or receiving a blood transfusion within the past 3 months.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • ORG-129

    is the reference capsule used in the study. It contains the active ingredient org‑129 and is taken by mouth. In the trial it serves as the standard product against which the new tablet form is compared, helping researchers see how much of the drug reaches the bloodstream from the capsule.

  • AGMB-129

    is the test tablet being evaluated. It also contains the active ingredient org‑129 and is taken orally. The study looks at how well this tablet is absorbed compared with the capsule and whether eating food changes how much of the drug gets into the body.

What is already known about the treatment

  • ORG-129

    This medication is taken by mouth as a 200 mg capsule. It is an experimental drug that is still being studied and is not yet approved for general medical use. The capsule is being tested for the treatment of fibrostenotic Crohn’s disease, a condition that causes narrowing of the intestine. It belongs to a class of oral anti‑inflammatory agents and works by reducing inflammation in the gut at the molecular level.

  • AGMB-129

    This medication is taken by mouth as a 200 mg tablet. Like ORG‑129, it is an experimental drug that has not received market approval and is being evaluated in clinical trials. The tablet is designed to treat fibrostenotic Crohn’s disease by helping to ease the narrowing and inflammation of the intestine. It is classified as an oral anti‑inflammatory agent and acts by targeting inflammatory pathways in the gut.

Investigated diseases

Fibrostenotic Crohn’s disease - Fibrostenotic Crohn’s disease is a form of Crohn’s disease where chronic inflammation leads to thickening and scarring of the intestinal wall. This scarring can cause narrowing, or strictures, that impede the passage of food through the gut. Over time, the strictures may become more pronounced, leading to episodes of abdominal pain and bowel obstruction. The disease typically progresses from inflammation to fibrosis, with the fibrotic changes becoming less reversible. Patients may experience intermittent flare‑ups of symptoms as the strictures evolve.
Trial detailsLast updated 16 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-504460-41-00Protocol codeAGMB-129-C103Estimated enrolment24 patientsSponsorAgomab Spain S.L.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.